We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
Read MoreHide Full Article
Key Takeaways
Teladoc adds SoloVitals and SoloScribe to strengthen its connected care platform for hospitals.
SoloVitals uses smartphone cameras to estimate heart and respiratory rates during virtual assessments.
SoloScribe creates clinical notes and transfers summaries to EHRs, reducing repetitive documentation work.
Teladoc Health, Inc. (TDOC - Free Report) is expanding its Solo connected care platform with two new AI-powered tools designed to make virtual consultations more useful for clinicians and less cumbersome for hospitals. SoloVitals and SoloScribe address different bottlenecks in remote care: obtaining timely patient information and documenting visits without pulling attention away from patients.
SoloVitals uses the camera on a smartphone or tablet to estimate heart and respiratory rates by detecting subtle changes in facial skin color. The contactless approach could give clinicians another source of information during virtual assessments. SoloScribe, meanwhile, generates structured clinical notes and transfers summaries into electronic health records (EHR), potentially reducing repetitive documentation work.
By bringing these capabilities together within Solo, Teladoc is making its platform more useful for hospitals seeking to simplify their technology systems. Already installed in more than 15,000 care locations worldwide, Solo integrates with EHR systems such as Epic and Oracle Health. SoloScribe is now generally available, while SoloVitals is currently available to select customers through a private preview. Teladoc expects SoloVitals to reach full general release in December 2026.
The expansion could also strengthen Teladoc's position in the increasingly competitive virtual healthcare market. By combining clinical documentation and remote patient assessment within one platform, Teladoc could help hospitals reduce administrative workloads, improve clinical workflows and deliver more efficient patient care.
The introduction of these tools adds another dimension to Teladoc's efforts to strengthen its enterprise healthcare business. Growing demand for AI-enabled healthcare solutions provides an opportunity to expand its reach, while its established presence among hospitals and health systems offers a foundation for adoption. Wider adoption of these capabilities could strengthen customer retention, increase platform utilization and support sustainable revenue growth, contributing to Teladoc's long-term growth prospects.
TDOC’s Price Performance
Over the past six months, TDOC’s shares have gained 5.9% compared with the industry’s growth of 11.6%.
The Zacks Consensus Estimate for Concentra Group’s current-year earnings of $1.65 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. CON beat earnings estimates in each of the trailing four quarters, with the average surprise being 16.3%. The consensus estimate for current-year revenues is pegged at $2.4 billion, suggesting 8.7% year-over-year growth.
The Zacks Consensus Estimate for Phibro Animal Health’s current-year earnings of $3.50 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. PAHC beat earnings estimates in each of the trailing four quarters, with the average surprise being 18.4%. The consensus estimate for current-year revenues is pegged at $1.6 billion, suggesting 3.8% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of 11 cents per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction. WGS beat earnings estimates in three of the trailing four quarters and missed once. The consensus estimate for current-year revenues is pegged at $478 million, suggesting 11.8% year-over-year growth.
View the Zacks #1 Rank List
Image: Shutterstock
Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
Key Takeaways
Teladoc Health, Inc. (TDOC - Free Report) is expanding its Solo connected care platform with two new AI-powered tools designed to make virtual consultations more useful for clinicians and less cumbersome for hospitals. SoloVitals and SoloScribe address different bottlenecks in remote care: obtaining timely patient information and documenting visits without pulling attention away from patients.
SoloVitals uses the camera on a smartphone or tablet to estimate heart and respiratory rates by detecting subtle changes in facial skin color. The contactless approach could give clinicians another source of information during virtual assessments. SoloScribe, meanwhile, generates structured clinical notes and transfers summaries into electronic health records (EHR), potentially reducing repetitive documentation work.
By bringing these capabilities together within Solo, Teladoc is making its platform more useful for hospitals seeking to simplify their technology systems. Already installed in more than 15,000 care locations worldwide, Solo integrates with EHR systems such as Epic and Oracle Health. SoloScribe is now generally available, while SoloVitals is currently available to select customers through a private preview. Teladoc expects SoloVitals to reach full general release in December 2026.
The expansion could also strengthen Teladoc's position in the increasingly competitive virtual healthcare market. By combining clinical documentation and remote patient assessment within one platform, Teladoc could help hospitals reduce administrative workloads, improve clinical workflows and deliver more efficient patient care.
The introduction of these tools adds another dimension to Teladoc's efforts to strengthen its enterprise healthcare business. Growing demand for AI-enabled healthcare solutions provides an opportunity to expand its reach, while its established presence among hospitals and health systems offers a foundation for adoption. Wider adoption of these capabilities could strengthen customer retention, increase platform utilization and support sustainable revenue growth, contributing to Teladoc's long-term growth prospects.
TDOC’s Price Performance
Over the past six months, TDOC’s shares have gained 5.9% compared with the industry’s growth of 11.6%.
Image Source: Zacks Investment Research
TDOC’s Zacks Rank & Key Picks
TDOC currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Medical space are Concentra Group Holdings Parent, Inc. (CON - Free Report) , Phibro Animal Health Corporation (PAHC - Free Report) and GeneDx Holdings Corp. (WGS - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Concentra Group’s current-year earnings of $1.65 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. CON beat earnings estimates in each of the trailing four quarters, with the average surprise being 16.3%. The consensus estimate for current-year revenues is pegged at $2.4 billion, suggesting 8.7% year-over-year growth.
The Zacks Consensus Estimate for Phibro Animal Health’s current-year earnings of $3.50 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. PAHC beat earnings estimates in each of the trailing four quarters, with the average surprise being 18.4%. The consensus estimate for current-year revenues is pegged at $1.6 billion, suggesting 3.8% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of 11 cents per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction. WGS beat earnings estimates in three of the trailing four quarters and missed once. The consensus estimate for current-year revenues is pegged at $478 million, suggesting 11.8% year-over-year growth.